Develop Your Drug Now
Pay Later
Welcome to the Future of Drug Discovery
Innovation is no longer a choice but a necessity in today’s pharmaceutical landscape. The journey from discovery to market takes many years and requires significant financial investment. With Syntekabio, you can accelerate your drug discovery today.
With our Develop Now, Pay Later program, Syntekabio invests in your success. Harness AI-driven drug discovery without upfront costs and maximize your potential for breakthrough results.
Start NowPartner with Syntekabio
Syntekabio is equipped to accelerate your entire drug discovery pipeline by leveraging our STB LaunchPad program, powered by our AI-driven DeepMatcher® technology platform. The program can deliver hits and optimized leads as well as IND-enabled compounds. Our ultimate goal is to bring our clients first-in-class or best-in-class candidates, fast.
See our AI survey- Compounds validated before you make significant R&D investment
- Highly flexible, physics-based, disease-agnostic AI platform that can identify novel small molecules, antibodies and cancer neoantigens
- Utilizes Flexible Molecular Docking (FMD) to continuously capture Protein-Ligand interactions/poses.
- Capabilities proven via successful industry collaborations and proprietary discovery
- Demonstrated outperformance of industry benchmarks
- Coverage of over 70% of human diseases
- Access to over 10 billion compounds as well as 1,400 in vitro/in vivo compatible drug targets
- Constant reconfiguration unnecessary, unlike target-specific models
Discover the Supercomputing Powerhouse that is Syntekabio’s AI
Our technology infrastructure is designed to exceed the demands of international pharmaceutical and biotechnology companies. Syntekabio’s Bio-Supercom Center houses 5,000 servers, 40,000 CPU cores, and 2,500 GPUs, powering the company’s AI algorithms. Our comprehensive suite of advanced tools is designed to accelerate the drug discovery and development process.
Download our brochureTake the Next Step: Discover How Syntekabio Can Support Your R&D Goals
Ready to accelerate your drug discovery process with an AI-driven solution designed to minimize risk and maximize results? We offer turbocharged speed, precision, and innovation.
Develop Now, Pay Later program, enabling you to initiate drug development without the typical financial constraints. Our program minimizes risk while allowing you to focus on achieving breakthrough results and pushing the boundaries of what’s possible.
Start today with a complimentary feasibility study of your target!
Meet Syntekabio at BioTechX USA 2024
Unlock the Future of Drug Discovery with AI-Driven Innovation
Join us at BioTechX USA, being held September 17-18, 2024 in Philadelphia, PA. Syntekabio is the Title Sponsor for the event and will give a keynote address and in-depth talk on its AI-driven solutions, as well as host a booth.
Don’t miss out on the latest insights in AI presented in our talks!
- 9:20 AM Tuesday, Sept. 17th - Keynote presentation Addressing Data Scarcity in Drug Discovery with Physics-based AI Models Jonathan Witztum, PhD, CTO, Syntekabio USA
- 5:05 PM Tuesday, Sept. 17th – AI in drug discovery presentation Flexible Molecular Docking for Neoantigen & Antibody Drug Prediction; Pre-Clinical Application Jongsun Jung, PhD, CEO, Syntekabio
Visit Booth #401 to meet the team and learn how our innovative AI-driven solutions can help solve your current pipeline challenges.
Book a meeting with us to secure your spot and discuss how we can drive your innovations forward!
Syntekabio Success Stories
-
DeepMatcher® Success Story
Successful Collaboration Between Syntekabio and QIMRB in Targeting Lung Diseases
Syntekabio and QIMRB, an Australian research institution, have embarked on a highly successful collaboration aimed at identifying potential therapeutic substances for treating chronic obstructive pulmonary disease (COPD) and lung cancer. Leveraging Syntekabio's AI-driven drug discovery platform, the collaboration identified a molecule with significant efficacy within just 5 months, with the company in preparation for future clinical trials.
- Rapid Identification of Promising Candidates: Using Syntekabio’s advanced AI-based platform, the collaboration swiftly identified top hits, including two Demethylase inhibitors, within 5 months of initiation. These molecules demonstrated significant potential in silico, paving the way for further efficacy confirmation studies by QIMRB.
- Breakthrough in Treating Lung Diseases: The AI-identified drug candidates have shown promising results in reducing inflammatory markers such as CCL2 and IRF1 in PBMCs (Peripheral Blood Mononuclear Cells) from COPD patients. Additionally, these compounds were effective in reducing lung damage, representing a potential breakthrough in the treatment of lung cancer, a disease with a 5-year survival rate of less than 18%.
- Global Impact on Lung Cancer and COPD Treatment: Lung cancer remains the second most common cancer worldwide and a leading cause of death, with 1 in 16 people being diagnosed in their lifetime. The success of this collaboration between Syntekabio and QIMRB offers hope for novel immunotherapy candidates that can address the limitations of current treatments, such as resistance to therapy and cancer recurrence.
-
DeepMatcher® Success Story
DeepMatcher® Hit Generation – Syntekabio’s Auto-BP Tool Outperforms Industry Benchmarks in Molecular Docking Accuracy
Syntekabio’s Auto-BP (Auto-Binding Pose) tool, part of DeepMatcher®, and its advanced accuracy in molecular docking enable drug developers to streamline the early stages of drug discovery. By identifying the best-fitting compounds for the binding site of a target protein of interest faster and more reliably, researchers can significantly accelerate the pipeline from hit identification to lead optimization, ultimately bringing new therapies to market more swiftly.
- Enhanced Precision: Auto-BP consistently achieves an RMSD (Root Mean Square Deviation from original structure) of less than 2.5, which is considered the gold standard for predicting binding accuracy. This metric indicates that Auto-BP can reliably identify how closely a drug fits into a protein’s active site, crucial for effective drug design.
- Benchmark Success: When compared to leading tools in the industry (DINC & IFD-MD), Auto-BP showed higher success rates in molecular docking, making it an indispensable tool for researchers aiming to shorten the drug development timeline.
- Real-World Applications: The superior performance of Auto-BP not only reduces the time spent on early drug discovery but also minimizes the costs associated with failed experiments. This allows pharmaceutical companies to focus resources on the most promising drug candidates.
-
DeepMatcher® Success Story
DeepMatcher® Lead Generation and Optimization Tool, ALGO Delivers Significant Improvements
Syntekabio’s ALGO (Auto-Lead Generation & Optimization) tool rapidly and significantly enhances the efficacy of lead compounds, giving clients a strategic advantage. By shortening the lead optimization phase, ALGO allows companies to move promising candidates into preclinical and clinical trials more quickly, reducing the overall time and cost of drug development. This is particularly critical in areas like oncology, where speed can directly impact patient outcomes.
- CLK2 Inhibitor: Within just 5 months, ALGO optimized a CLK2 inhibitor, enhancing its efficacy by 32-fold. This dramatic improvement underscores ALGO’s potential to refine drug candidates quickly and effectively.
- IDO/TDO Dual Inhibitor (STB-C017): By employing a data-driven AI model Syntkebaio was able to optimize a dual inhibitor targeting IDO and TDO, two critical enzymes in immune-oncology. Over 12 months, the model improved the inhibitor’s potency by 14-fold, showcasing the platform’s capability in complex therapeutic areas.
- FLT3 Inhibitor: For the FLT3 target, ALGO achieved a 6.5-fold improvement in efficacy in just 5 months, with 6 out of 7 optimized compounds showing significant enhancements. This quick turnaround is vital for staying ahead in competitive therapeutic landscapes.
-
DeepMatcher® Success Story
The Superiority of Syntekabio's Flexible Molecular Docking (FMD) Approach in Drug Discovery
Syntekabio’s AI-driven DeepMatcher® platform leverages Flexible Molecular Docking (FMD) to offer substantial improvements over traditional Rigid Molecular Docking (RMD). By incorporating protein flexibility, FMD enhances the accuracy of pose predictions, increases the likelihood of discovering viable drug candidates, and can potentially shorten development timelines, providing a significant edge in drug discovery.
- Enhanced Accuracy in Pose Predictions: FMD accounts for the natural flexibility of proteins, leading to more accurate pose predictions, which can achieve accuracy levels between 80-95%. This is a notable improvement over RMD, which typically offers accuracy rates of 50-75%. This higher precision aids in more confidently identifying potential drug candidates.
- Increased Likelihood of Viable Hits: FMD’s flexible approach expands the opportunity to identify promising hits and leads, often resulting in 6-8 good hits and 3-4 optimized leads. In comparison, RMD tends to produce fewer hits, often only 1-2, due to its rigid nature. This broader range of potential candidates early in the process enhances the chances of finding effective therapies.
- Potential for Faster Development: FMD has the capability to reduce the overall timeline for drug discovery, potentially shortening the process from the typical 5-7 years associated with RMD to as little as 2 years. This accelerated timeline can bring viable drug candidates to the preclinical stage more quickly, enhancing the efficiency of the drug development pipeline.
-
Syntekabio Technology Success Stories
Biologics: In Silico Antibody – PD-L1 Case Study
Syntekabio’s Ab-ARS™ platform demonstrates the power of in silico methods in biologics discovery. By delivering antibody candidates that outperform existing drugs, the platform offers pharmaceutical companies a faster and more cost-effective route to developing next-generation therapies. This is particularly important in the context of cancer treatment, where the ability to quickly develop effective, targeted therapies can have a profound impact on patient survival rates.
- Superior Antibody Candidate: Ab-ARS™ identified a new antibody candidate that binds more effectively to the PD-L1 protein than atezolizumab, an approved PD-L1 inhibitor used in cancer therapy. This improved binding affinity suggests that the new candidate could potentially offer better therapeutic outcomes.
- Efficient Discovery Process: The in silico (computer-based) approach used by Ab-ARS™ significantly speeds up the discovery process. By leveraging advanced algorithms, the platform can screen vast libraries of compounds and predict their interactions with target proteins much faster than traditional methods.
-
Syntekabio Technology Success Stories
Metaclipse Collaboration: Personalized NeoAntigen Prediction
The NEO-ARS™ platform’s success in identifying and validating neoantigens represents a significant breakthrough in personalized medicine. By enabling the development of therapies tailored to individual patients’ unique cancer profiles, Syntekabio is helping to pave the way for more effective and less toxic cancer treatments. This approach not only improves patient outcomes but also opens new avenues for research in immuno-oncology.
- NEO-ARS™ Platform: Syntekabio’s platform accurately identifies neoantigens—unique markers on cancer cells that can be targeted by the immune system. These neoantigens are validated using ex vivo IFN-γ ELISpot assays, confirming the platform’s precision in predicting effective targets for personalized cancer therapies.
- High-Purity Synthesis: The neoantigens identified by NEO-ARS™ were synthesized with over 95% purity, ensuring that the resulting peptides were highly specific to the patient’s cancer cells. This high level of specificity is crucial for effective personalized therapies.
- Immune Response: The synthesized peptides successfully activated T-cells, a critical component of the immune response against cancer. This demonstrates the platform’s potential to generate effective, patient-specific cancer treatments that harness the body’s own immune system.
- FDA Clearance: Metaclipse’s proprietary cancer vaccine, supported by Syntekabio’s technology, has received clearance from the US FDA to proceed with a phase 1 clinical trial. This marks a significant milestone in the development of the vaccine, which leverages patient-specific neoantigens identified by NEO-ARS™.
Frequently Asked Questions
Subscribe to our email listWhat is your “Develop Now, Pay Later“ model?
Our model allows you to use Syntekabio’s platform to test the validity of your target compound or protein without upfront costs, minimizing financial risk and enabling you to innovate with confidence.
How does your complimentary feasibility study work?
We conduct a comprehensive analysis of your target protein to determine its viability. If successful, you can move forward with confidence. If not, you can walk away without any obligation.
What types of drug targets does STB LaunchPad support?
STB LaunchPad supports a wide range of therapeutic areas representing 70% of all human diseases. Syntekabio’s AI-driven platform accesses over 1,400 drug targets compatible with in vitro and in vivo testing.
How quickly can I expect results?
Hit discovery can be achieved in 3 to 5 months, lead optimization in 6 to 10 months, and animal testing in 6 to 12 months.
